Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms

Thrombosis and Haemostasis

Volumn 106, Issue 1, 2011, Pages 90-101

  Mishra, Niraj ^a   Vercauteren, Ellen ^a   Develter, Jan ^a   Bammens, Riet ^a   Declerck, Paul J ^a   Gils, Ann ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Epitope mapping; Fibrinolysis; Human tafi; Monoclonal antibody; Tafiinhibitors

Indexed keywords

ENZYME INHIBITOR; EPITOPE; HEMATOLOGIC AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TCK11A9; MONOCLONAL ANTIBODY TCK22G2; MONOCLONAL ANTIBODY TCK27A4; PLASMIN; POTATO TUBER CARBOXYPEPTIDASE INHIBITOR; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ARTICLE; BLOOD CLOT LYSIS TIME; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; MUTAGENESIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; WILD TYPE;

EID: 79960069147     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-08-0546     Document Type: Article

References (51)

1. Bouma BN, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 2003; 1: 1566-1574.
2. Bouma BN, Marx PF, Mosnier LO, et al. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 2001; 101: 329-354.
3. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-16608.
4. Hendriks D, Wang W, Scharpé S, et al. Purification and characterization of a new arginine carboxypeptidase in human serum. Biochim Biophys Acta 1990; 1034: 86-92.
5. Eaton DL, Malloy BE, Tsai SP, et al. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-21838.
6. Tan AK, Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry 1995; 34: 5811-5816.
7. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-14484.
8. Boffa MB, Bell R, Stevens WK, et al. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 2000; 275: 12868-12878.
9. Marx PF, Hackeng TM, Dawson PE, et al. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. J Biol Chem 2000; 275: 12410-12415.
10. Marx PF, Dawson PE, Bouma BN, et al. Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry 2002; 41: 6688-6696.
11. Hillmayer K, Macovei A, Pauwels D, et al. Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI) - a comparative study assessing the biological equivalence of rat, murine and human TAFI. J ThrombHaemost 2006; 4: 2470-2477.
12. Schneider M, Boffa MB, Stewart R, et al. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277: 1021-1030.
13. Leurs J, Hendriks D. Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease. Thromb Haemost 2005; 94: 471-487.
14. Redlitz A, Tan AK, Eaton DL, et al. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-2538.
15. Campbell WD, Lazoura E, Okada N, et al. Inactivation of C3a and C5a octapeptides by carboxypeptidase Rand carboxypeptidase N. Microbiol Immunol 2002; 46: 131-134.
16. Myles T, Nishimura T, Yun TH, et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278: 51059-51067.
17. te Velde EA, Wagenaar GTM, Reijerkerk A, et al. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2003; 1: 2087-2096.
18. Asai S, Sato T, Tada T, et al. Absence of procarboxypeptidase R induces complement- mediated lethal inflammation in lipopolysaccharide primed mice. J Immunol 2004; 173: 4669-4674.
19. Boffa MB, Koschinsky ML. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem 2007; 40: 431-442.
20. Willemse JL, Heylen E, Nesheim ME, et al. Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy? J Thromb Haemost 2009; 7: 1962-1971.
21. Boffa MB, Wang W, Bajzar L, et al. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin dependent activation, thermal stability, and enzymatic properties. J Biol Chem 1998; 273: 2127-2135.
22. Rawlings ND, Morton FR, Barrett AJ. MEROPS: the peptidase database. Nucleic Acids Res 2006; 34: 270-272.
23. Vendrell J, Querol E, Aviles FX. Metallocarboxypeptidases and their protein inhibitors: Structure, function and biomedical properties. Biochim Biophys Acta 2000; 1477: 284-298.
24. Schneider M, Nesheim M. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis. J ThrombHaemost 2003; 1: 147-154.
25. Walker JB, Hughes B, James I, et al. Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro. J Biol Chem 2003; 278: 8913-8921.
26. Hillmayer K, Vancraenenbroeck R, De Maeyer M, et al. Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor. J Thromb Haemost 2008; 6: 1892-1899.
27. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-2100.
28. Bouma BN, Mosnier LO, Meijers JC, et al. FactorXI dependent and independent activation of thrombin activatable fibrinolysis inhibitor (TAFI) in plasma associated with clot formation. Thromb Haemost 1999; 82: 1703-1708.
29. Gils A, Ceresa E, Macovei AM, et al. Modulation of TAFI function through different pathways: implications for the development of TAFI inhibitors. J Thromb Haemost 2005; 3: 2745-2753.
30. Ceresa E, Peeters M, Declerck P.J., et al. Announcing a TAFIamutant with a 180-fold increased half-life and concomitantly a strongly increased antifibrinolytic potential. J Thromb Haemost 2007; 5: 418-420.
31. Gils A, Alessi MC, Brouwers E, et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23: 1122-1127.
32. Hillmayer K, Brouwers E, León-Tamariz F, et al. Development of sandwich-type ELISAs for the quantification of rat and murine thrombin activatable fibrinolysis inhibitor in plasma. J Thromb Haemost 2008; 6: 132-138.
33. Ceresa E, Brouwers E, Peeters M, et al. Development of ELISAs measuring the extent of TAFI activation. Arterioscler Thromb Vasc Biol 2006; 26: 423-428.
34. Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry 1978; 15: 429-436.
35. Nakane PK, Kawaoi A. Peroxidase-labeled antibody: a new method of conjugation. J Histochem Cytochem 1974; 22: 1084-1091.
36. Buelens K, Hassanzadeh-Ghassabeh G, Muyldermans S, et al. Generation and characterization of inhibitory nanobodies towards Thrombin Activatable Fibrinolysis Inhibitor. J Thromb Haemost 2010; 8: 1302-1312.
37. Morange PE, Juhan-Vague I, Scarabin PY, et al. Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. Thromb Haemost 2003; 89: 554-560.
38. Silveira A, Schatteman K, Goossens F, et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-368.
39. Montaner J, Ribo M, Monasterio J, et al. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 2003; 34: 1038-1040.
40. Juhan-Vague I, Morange PE, Aubert H, et al. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 2002; 22: 867-873.
41. van-Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-2859.
42. Polla MO, Tottie L, Norden C, et al. Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa). Bioorg Med Chem 2004; 12: 1151-1175.
43. Do YH, Gifford-Moore DS, Beight DW, et al. Inhibition of thrombin activatable fibrinolysis inhibitor by cysteine derivatives. Thromb Res 2005; 116: 265-271.
44. Mosnier LO, von-dem-Borne PA, Meijers JC, et al. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-835.
45. Mutch NJ, Moore NR, Wang E, et al. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. J ThrombHaemost 2003; 1: 2000-2007.
46. Guimaraes AH, Rijken DC. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model. Thromb Haemost 2004; 91: 473-479.
47. Leurs J, Wissing BM, Nerme V, et al. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma. Thromb Haemost 2003; 89: 264-271.
48. Miah MF, Boffa MB. Functional analysis of mutant variants of thrombin-activatable fibrinolysis inhibitor resistant to activation by thrombin or plasmin. J Thromb Haemost 2009; 7: 665-672.
49. Vercauteren E, Emmerechts J, Peeters M, et al. Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model. Blood 2011; 117: 4615-4622.
50. Wu C, Kim PY, Manuel R, et al. The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex. J Biol Chem 2009; 284: 7059-7067.
51. Marx PF, Brondijk TH, Plug T, Romijn RA, Hemrika W, Meijers JC, Huizinga EG. Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation. Blood 2008; 112: 2803-2809.